(Q40028104)

16 September 2017

Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model (English)

1 reference

16 September 2017

1 reference

cervix uterine cancer

1 reference

6

William E Grizzle

1 reference

16 September 2017

James E Kendrick

1

1 reference

16 September 2017

J Michael Straughn

2

1 reference

16 September 2017

Patsy G Oliver

3

1 reference

16 September 2017

Wenquan Wang

4

1 reference

16 September 2017

Li Nan

5

1 reference

16 September 2017

Cecil R Stockard

7

1 reference

16 September 2017

Ronald D Alvarez

8

1 reference

16 September 2017

Donald J Buchsbaum

9

1 reference

16 September 2017

language of work or name

English

0 references

publication date

4 January 2008

1 reference

16 September 2017

1 reference

16 September 2017

108

1 reference

16 September 2017

591-597

1 reference

16 September 2017

3

1 reference

The epidemiology of cervical cancer

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Safety and antitumor activity of recombinant soluble Apo2 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Identification and characterization of a new member of the TNF family that induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

A novel receptor for Apo2L/TRAIL contains a truncated death domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

The receptor for the cytotoxic ligand TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

A new instrument for the rapid preparation of tissue slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

On testing for drug/chemical interactions: definitions and inference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Apoptosis, cancer and the p53 tumour suppressor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Mitochondrial regulation of apoptotic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Death and anti-death: tumour resistance to apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

Down regulation of p53 with HPV E6 delays and modifies cell death in oxidant response of human diploid fibroblasts: an apoptosis-like cell death associated with mitosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.039

10.1016/J.YGYNO.2007.11.039

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference